Commentary: Let the tail wag the dog: The case for radioimmunotherapy of low-grade follicular lymphoma

Oncologist

Volumn 13, Issue 6, 2008, Pages 655-656

  Plastaras, John P ^a   Glatstein, Eli ^a   Schuster, Stephen J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Disease free survival; Follicular lymphoma; Ibritumomab tiuxetan; Iodine 131 tositumomab; Radioimmunotherapy; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB Y 90; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; HUMAN; NOTE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 46149093002     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0113     Document Type: Note

References (15)

1. Petersen PM, Gospodarowicz M, Tsang R. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. Proc Am Soc Clin Oncol 2004;23:563s.
2. Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 1986;4:1470-1480.
3. Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 1995;13:140-147.
4. Buchegger F, Press OW, Bischof Delaloye A et al. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. The Oncologist 2008;13:657-667.
5. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732.
6. Hochster HS, Weller E, Gascoyne RD et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (ASH Annual Meeting Abstracts) 2005;106:349.
7. Marcus RE, Solal-Celigny P, Imrie K et al. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2006;108:481.
8. Fisher RI, Kaminski MS, Wahl RL et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-7573.
9. Kaminski MS, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-449.
10. Deconinck E, Foussard C, Milpied N et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood 2005;105:3817-3823.
11. Sebban C, Mounier N, Brousse N et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006;108:2540-2544.
12. Hagenbeek A, Bischof-Delaloye A, Radford JA et al. 90Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: First results of the international randomized phase 3 First-line Indolent Trial (FIT) in 414 patients. Blood 2007;110:643.
13. Press OW, Unger JM, Braziel RM et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-4149.
14. Berenson A. Market forces cited in lymphoma drugs' disuse. New York Times, July 14, 2007:1.
15. Garber K. Users fear that lymphoma drugs will disappear. J Natl Cancer Inst 2007;99:498-499, 501.